Oruka Therapeutics Reports Positive Interim Data from ORKA-002 Phase 1 Trial
Oruka Therapeutics announced positive interim data from its Phase 1 trial of ORKA-002 and updates from the ongoing trials of ORKA-001. Key highlights; ORKA-002 interim Phase 1 data demonstrates a half-life of 75-80 days supporting potential for twice-per-year dosing in psoriasis and quarterly dosing in hidradenitis suppurativa; Phase 2 studies for ORKA-002 expected to begin in 1H 2026 for psoriasis and 2H 2026 for hidradenitis suppurativa; First patients dosed in EVERLAST-B Phase 2b trial of ORKA-001 in December 2025 with data expected in 2027
